Results 81 to 90 of about 147,721 (313)

Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study

British Journal of Clinical Pharmacology, EarlyView.
Aim We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish ...
Sofia Attelind, Niclas Eriksson, Marco Cavalli, Yiyi Xu, Fredrik Nyberg, Anders Sundström, Mia Wadelius, Pär Hallberg   +7 more
wiley   +1 more source

Usage and safety of direct oral anticoagulants at patients with atrial fibrillation and planned diagnostic procedures, interventions, and surgery

Heart and Mind, 2019
Atrial fibrillation (AF) affects about 2% of the population, with the increasing prevalence with age. It is associated with poorer quality of life, effort intolerance, frequent hospitalizations, heart failure, and increased risk of systemic embolization,
Marko Mornar Jelavic, Goran Krstacic, Hrvoje Pintaric   +2 more
doaj   +1 more source

Myocardial infarction, prothrombotic genotypes, and venous thrombosis risk: The Tromsø Study

Research and Practice in Thrombosis and Haemostasis, 2020
Background The risk of venous thromboembolism (VTE) is increased after a myocardial infarction (MI). Some prothrombotic genotypes associated with VTE have also been associated with risk of MI.
Joakim K. Sejrup, Vania M. Morelli, Maja‐Lisa Løchen, Inger Njølstad, Ellisiv B. Mathiesen, Tom Wilsgaard, John‐Bjarne Hansen, Sigrid K. Brækkan   +7 more
doaj   +1 more source

Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER) [PDF]

, 2010
Venous thromboembolism (VTE) prophylaxis remains underutilized, particularly in cancer patients. We explored clinical predictors of prophylaxis in hospitalized cancer patients before the onset of acute ...
Korte, W, Spirk, D., Korte, W., Banyai, M, Nobel, D, Kucher, N, Spirk, D, Kucher, N., Mazzolai, L, Banyai, M., Bounameaux, H, Mazzolai, L., Nobel, D., Bounameaux, H., Baumgartner, I., Baumgartner, I, Bounameaux, Henri   +16 more
core   +1 more source

Catheter Thrombectomy of Massive Pulmonary Embolism Secondary to Spongostan Embolisation: A Case Report

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Novel adjuvant hemostatic agents are increasingly used in surgical procedures to achieve hemostasis. We present a case of embolisation of hemostatic agents during a neurosurgical operation, causing massive PE requiring venoarterial extracorporeal membrane oxygenation support, in a 7‐year‐old boy.
Talya Finke, Oshry Mozes, Itai Pessach, Sharon Borik Chiger   +3 more
wiley   +1 more source

A Review of Virtual Twins in Physiologically‐Based Pharmacokinetic Modeling and Simulation

Clinical Pharmacology &Therapeutics, EarlyView.
The novel application of Virtual Twins (VT) in PBPK (VT‐PBPK) presents the opportunity to advance precision dosing and accelerate the shift from one‐size‐fits‐all to targeted, individualized treatments. This review aims to: (1) critically evaluate existing research on the use of VTs in PBPK, (2) develop a conceptual definition of VT‐PBPK, (3) describe ...
Emily Mannix, Sam Mostafa, Amin Rostami‐Hodjegan, Thomas M. Polasek, Carl M. J. Kirkpatrick   +4 more
wiley   +1 more source

Non-valvular atrial fibrillation and stroke : implications for management [PDF]

, 1995
Nonvalvular Atrial Fibrillation is more prevalent with increasing age. It is associated with a six-fold excess risk of stroke; and a cumulative lifetime stroke risk of 35%. 15% of ischaemic strokes are directly attributable to it.
Tilney, Myra Kay
core  

Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients [PDF]

, 2016
Background Patients hospitalized for acute medical illness are at increased risk for venous thromboembolism. Although risk assessment is recommended and several at-admission risk assessment models have been developed, these have not been adequately ...
Spyropoulos, AC, Greene, MT, Flanders, SA, Grant, PJ, Chopra, V, Bernstein, SJ, Kaatz, S   +6 more
core   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. [PDF]

, 2005
Thrombophilia is the term now used to describe predisposition to increased risk of venous and occasionally arterial thromboembolism due to hematological abnormalities.
Conard J., The European Genetics Foundation, The Mediterranean League on Thromboembolism, Kalodiki E., COCCHERI, SERGIO, Research Trust, Xenophonthos S., Michiels J.J., Haas S., Hull R., Guermazi S., Nicolaides A.N., Carpenter P., Gerotziafas G., The Cardiovascular Disease Educational, Myers K., Pineo G., Samama M.M., De Stefano V., Elkoofy N., Simonian S., ROMEO, GIOVANNI, Breddin H.K., The International Union of Angiology, Prandoni P., Kristof V.   +25 more
core